{"id":"NCT03147248","sponsor":"Celltrion","briefTitle":"A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA","officialTitle":"A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-12","primaryCompletion":"2018-05-21","completion":"2019-04-15","firstPosted":"2017-05-10","resultsPosted":"2020-04-08","lastUpdate":"2020-04-08"},"enrollment":407,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]},{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]},{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]},{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]},{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]},{"type":"BIOLOGICAL","name":"CT-P13","otherNames":["Infliximab"]}],"arms":[{"label":"Cohort 1: CT-P13 IV 3 mg/kg","type":"ACTIVE_COMPARATOR"},{"label":"Cohort 2: CT-P13 SC 90 mg","type":"EXPERIMENTAL"},{"label":"Cohort 3: CT-P13 SC 120 mg","type":"EXPERIMENTAL"},{"label":"Cohort 4: CT-P13 SC 180 mg","type":"EXPERIMENTAL"},{"label":"Arm 1: CT-P13 SC 120 mg","type":"EXPERIMENTAL"},{"label":"Arm 2: CT-P13 IV 3 mg/kg","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).","primaryOutcome":{"measure":"Area Under the Concentration-time Curve (AUCÏ„) of Infliximab at Steady State (Part 1)","timeFrame":"Weeks 22 (pre-dose to 216 hours post-dose), 24 (14 days after start of administration [SOA] at Week 22), 26 (pre-dose) and 28 (42 days after SOA at Week 22), and Week 30 (pre-dose)","effectByArm":[{"arm":"Cohort 1: CT-P13 IV 3 mg/kg (Part 1)","deltaMin":12032957.5,"sd":5345598.59},{"arm":"Cohort 2: CT-P13 SC 90 mg (Part 1)","deltaMin":5047724.2,"sd":2449771.86},{"arm":"Cohort 3: CT-P13 SC 120 mg (Part 1)","deltaMin":7333767,"sd":2765064.19},{"arm":"Cohort 4: CT-P13 SC 180 mg (Part 1)","deltaMin":9930696.6,"sd":3208367.37}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["36534825","33230526"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Localized injection site reaction","Viral upper respiratory tract infection","Upper respiratory tract infection","Urinary tract infection","Headache"]}}